CClinicalTrials.gg
Status unknownNCT02350270Updated Jan 29, 2015

Gait, cOgnitiOn & Decline (GOOD)

An observational study in Mild Cognitive Impairment, Mild Dementia and Moderate Dementia, sponsored by University Hospital, Angers. Status unknown at 1 site in France. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-29.

Sponsored by University Hospital, Angers · Observational

The sponsor has not verified this record recently (last verified Feb 2014), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
2,800
Ages
60 Years and older
Sex
All
01

Study summary

The main objective of the GOOD initiative was to determine which spatio-temporal gait parameters and/or combination(s) of spatio-temporal gait parameters best differentiate between cognitively healthy individuals (CHI), patients with mild cognitive impairment (MCI) and those with mild and moderate dementia.

Read the detailed description

Gait disorders are frequent in individuals with cognitive disorders. However, the profile of spatio-temporal gait parameters in the different cognitive status in aging (from normal cognition to dementia) has been poorly studied. Determining this profile associated with the severity of cognitive disorders may be helpful to understand the complex interplay between gait and cognitive disorders and, thus, may have important implication for the diagnosis process of patients with and without dementia. For instance, defining a motor phenotype of the severity of cognitive disorders by using quantitative gait measurements could be used to improve the prediction and the diagnosis of dementia.

The investigators hypothesized that, compared to CHI, people with MCI and mild dementia could be characterized by specific phenotypes of spatio-temporal gait parameters measured with the GAITRite® system, and that these profiles could be explained by declines in domain-specific cognitive performance.

02

Conditions studied

  • Mild Cognitive Impairment
  • Mild Dementia
  • Moderate Dementia
  • Healthy

Keywords

  • cognitively healthy individuals
03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's planned enrollment of 2,800 is above the median of 250 across 482 observational studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients were recruited in each memory clinic by a physician

Inclusion criteria

  • Being 60 years old and older
  • Ability to answer questions

Exclusion criteria

Exclusion Criteria:

  • Opposition to the use of information collected for research purposes
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
2,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • cognitively healthy individuals (CHI)

    CHI were participants without objective cognitive impairment

    Other: gait and cognitive testing

  • mild cognitive impairment (MCI)

    MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment

    Other: gait and cognitive testing

  • mild and moderate dementia

    Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences

    Other: gait and cognitive testing

Interventions

  • Othergait and cognitive testing
06

What researchers measure

Primary outcomes

  1. Spatio-temporal gait parameters

    Spatio-temporal gait parameters were measured at steady state walking using GAITRite®-system.

    Time frame: This outcome is assessed at inclusion

Secondary outcomes

  1. Clinical assessment

    This outcome was assessed by a questionnaire.

    Time frame: This outcome is assessed at inclusion

  2. Cognitive status

    Cognitive status was assessed by cognitive testing.

    Time frame: This outcome is assessed at inclusion

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Angers, 49933, France
    • Olivier Beauchet, MD, PhD · Contact · olbeauchet@chu-angers.fr · ++33 2 41 35 57 38
    • Olivier Beauchet, MD, PhD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02350270
Lead sponsor
University Hospital, Angers
Collaborators
Biomathics
Responsible party
Sponsor
First posted
Jan 29, 2015
Start date
Jan 2015
Primary completion
Jun 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Jan 29, 2015

Study contacts

Olivier Beauchet, MD, PhD
Contact
olbeauchet@chu-angers.fr
++33 2 41 35 57 38
Olivier Beauchet, MD, PhD
principal investigator · Angers University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion